Surufatinib combined with TAS-102 as a late-line therapy in patients with metastatic pancreatic cancer (mPDAC): Updated results of a single-arm, phase II trial.

Details

Language :

English

ISSN :

0732183X

Volume :

43

Database :

Supplemental Index

Journal :

Journal of Clinical Oncology

Publication Type :

Academic Journal

Accession number :

182479440

Full Text :

https://doi.org/10.1200/JCO.2025.43.4_suppl.739